Decreased Ceftriaxone Susceptibility in Emerging (35B and 6C) and Persisting (19A) Streptococcus pneumoniae Serotypes in the United States, 2011-2012: Ceftaroline Remains Active
            <i>In Vitro</i>
            among β-Lactam Agents

Mendes, Rodrigo E.; Biek, Donald; Critchley, Ian A.; Farrell, David J.; Sader, Hélio S.; Jones, Ronald N.

doi:10.1128/aac.02976-14

Cited by 21 publications

(16 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Ceftriaxone nonsusceptibility represented Ͻ10% in our study; this percentage differs from an antimicrobial resistance surveillance program that reported 29.7% ceftriaxone nonsusceptibility among serotype 35B isolates obtained mainly from the East South Central and South Atlantic U.S. Census regions (30). In the present study, different rates of resistance to erythromycin and TMP-SMX were observed, but resistance to clindamycin was rare (1%).…”

Section: Fig 4 Eburst Analysis Of Penicillin Mic Distribution and Mulcontrasting

confidence: 52%

Emergence of Multidrug-Resistant Pneumococcal Serotype 35B among Children in the United States

et al. 2017

View full text Add to dashboard Cite

Streptococcus pneumoniae serotype 35B is a nonvaccine serotype associated with high rates of penicillin nonsusceptibility. An increase in the proportion of multidrug-resistant (MDR) 35B isolates has recently been reported. The genetic events contributing to the emergence of MDR serotype 35B are unknown. The sequence type (ST) composition of 78 serotype 35B isolates obtained from pediatric patients with invasive pneumococcal disease from 1994 to 2014 and 48 isolates from pediatric patients with otitis media (noninvasive) from 2011 to 2014 was characterized by multilocus sequence typing (MLST). The most common STs were ST558 (69.2%), ST156 (10.3%), and ST452 (3.8%). Two major clonal complexes (CC), CC558 and CC156, were identified by eBURST analysis. Overall, 91% (71/78) of isolates were penicillin nonsusceptible and 16.7% (13/78) were MDR. Among all invasive serotype 35B isolates, MDR isolates increased significantly, from 2.9% (1/35) to 27.9% (12/43) (P ϭ 0.004), after the 13-valent pneumococcal conjugate vaccine (PCV13) was introduced. All CC156 isolates were identified after the introduction of PCV13 (0/35 [0%] before versus 9/43 [20.9%] after; P ϭ 0.003) and were MDR. All CC156 isolates had similar antimicrobial susceptibility patterns; in contrast, high variability in antimicrobial susceptibility was observed among CC558 isolates. The distributions of CC558 and CC156 among invasive and noninvasive isolates were not different. The increased prevalence of MDR serotype 35B after the introduction of PCV13 was directly associated with the emergence of ST156. Genotyping suggests that capsular switching has occurred between MDR vaccine serotypes belonging to ST156 (e.g., 9V, 14, and 19A) and serotype 35B.

show abstract

Section: Fig 4 Eburst Analysis Of Penicillin Mic Distribution and Mulcontrasting

confidence: 52%

Emergence of Multidrug-Resistant Pneumococcal Serotype 35B among Children in the United States

et al. 2017

View full text Add to dashboard Cite

show abstract

“…First, although the percentage of penicillin non susceptible pneumococci was high (38%), comparing with the value reported from French bloodstream isolates (22.4%; 2013 ECDC data, 2013, http://www.ecdc.europa.eu) or from European respiratory tract specimens (17.9%), no strain was highly resistant to amoxicillin, cefotaxime, or ceftaroline (Farrell et al, 2013). This comforting statement should be carefully monitored: in the United States, emerging serotypes exhibiting a high resistance to thirdgeneration cephalosporins have been reported (Mendes et al, 2014). In the work of Mendes et al (2014), ceftaroline in vitro activity was fortunately conserved; the MIC 50 and MIC 90 values of this new compound were 0.008 and 0.12 mg/L, respectively, in our samples of strains.…”

Section: Antimicrobial Susceptibilities Of Respiratory Pathogensmentioning

confidence: 58%

Distribution and antimicrobial susceptibility of bacteria from adults with community-acquired pneumonia or complicated skin and soft tissue infections in France: the nationwide French PREMIUM study

Leprince

Desroches

Emirian

et al. 2015

Diagnostic Microbiology and Infectious Disease

View full text Add to dashboard Cite

The empirical therapy of community-acquired pneumonia (CAP) and complicated skin and soft tissue infections (cSSTIs) must be based on updated bacterial distribution and susceptibility data. A nationwide study consecutively collected 1288 isolates from CAP (n=467) and cSSTIs (n=821) from 18 French hospitals between 2012 and 2013. The MIC values of commonly used antimicrobial agents, including ceftaroline, were determined. Bacterial distribution featured Pneumococcus, Haemophilus influenzae, and Staphylococcus aureus for CAPs and S. aureus, β-hemolytic streptococci and Enterobacteriaceae for cSSTIs. Antimicrobial susceptibility testing indicated i) the sustained third-generation cephalosporins and levofloxacin activity against pneumococci and H. influenzae, ii) no methicillin-resistant Staphylococcus aureus emergence among respiratory pathogens, iii) the high in vitro activity of ceftaroline against staphylococci from cSSTIs (98.7% susceptibility), and iv) the worrisome decreasing fluoroquinolone and third-generation cephalosporin susceptibilities among Enterobacteriaceae. This laboratory-based survey depicts a contrasting situation and supports the scoring of patients for the resistant pathogen risk before empirical therapy.

show abstract

“…Interestingly, 3 of the 4 penicillin-nonsusceptible CCs have been commonly associated with the closely related serotype 6A (291), suggesting that much of the increase in the prevalence of serotype 6C IPD (mostly in adults, where it caused a significant disease burden) and the increased resistance originated from independent serotype switch events involving individual type 6A capsular locus recipients. Increasing proportions of clinical isolates within serotypes 35B and 6C in the United States with decreased susceptibility to ␤-lactams have been reported (295). Resistant serotype 35B (serotype 35B/ST558) IPD was virtually absent among children in the preconjugate vaccine era, but during the past decade, serotypes 35B, 6C, and additional serotypes have increased in both carriage (296,297) and IPD cases representing all ages (50,294,295), potentially as a consequence of the removal of competing conjugate vaccine serotypes from the pediatric carriage reservoir.…”

Section: Current Moderately Successful Antibiotic-resistant Nonvaccinmentioning

confidence: 99%

“…Increasing proportions of clinical isolates within serotypes 35B and 6C in the United States with decreased susceptibility to ␤-lactams have been reported (295). Resistant serotype 35B (serotype 35B/ST558) IPD was virtually absent among children in the preconjugate vaccine era, but during the past decade, serotypes 35B, 6C, and additional serotypes have increased in both carriage (296,297) and IPD cases representing all ages (50,294,295), potentially as a consequence of the removal of competing conjugate vaccine serotypes from the pediatric carriage reservoir. The PMEN-24 serotype 35B clonal complex has emerged to become the predominant pediatric ␤-lactam-resistant IPD serotype (50).…”

Section: Current Moderately Successful Antibiotic-resistant Nonvaccinmentioning

confidence: 99%

Biological and Epidemiological Features of Antibiotic-Resistant Streptococcus pneumoniae in Pre- and Post-Conjugate Vaccine Eras: a United States Perspective

et al. 2016

View full text Add to dashboard Cite

SUMMARYStreptococcus pneumoniaeinflicts a huge disease burden as the leading cause of community-acquired pneumonia and meningitis. Soon after mainstream antibiotic usage, multiresistant pneumococcal clones emerged and disseminated worldwide. Resistant clones are generated through adaptation to antibiotic pressures imposed while naturally residing within the human upper respiratory tract. Here, a huge array of related commensal streptococcal strains transfers core genomic and accessory resistance determinants to the highly transformable pneumococcus. β-Lactam resistance is the hallmark of pneumococcal adaptability, requiring multiple independent recombination events that are traceable to nonpneumococcal origins and stably perpetuated in multiresistant clonal complexes. Pneumococcal strains with elevated MICs of β-lactams are most often resistant to additional antibiotics. Basic underlying mechanisms of most pneumococcal resistances have been identified, although new insights that increase our understanding are continually provided. Although all pneumococcal infections can be successfully treated with antibiotics, the available choices are limited for some strains. Invasive pneumococcal disease data compiled during 1998 to 2013 through the population-based Active Bacterial Core surveillance program (U.S. population base of 30,600,000) demonstrate that targeting prevalent capsular serotypes with conjugate vaccines (7-valent and 13-valent vaccines implemented in 2000 and 2010, respectively) is extremely effective in reducing resistant infections. Nonetheless, resistant non-vaccine-serotype clones continue to emerge and expand.

show abstract

Decreased Ceftriaxone Susceptibility in Emerging (35B and 6C) and Persisting (19A) Streptococcus pneumoniae Serotypes in the United States, 2011-2012: Ceftaroline Remains Active In Vitro among β-Lactam Agents

Cited by 21 publications

References 18 publications

Emergence of Multidrug-Resistant Pneumococcal Serotype 35B among Children in the United States

Emergence of Multidrug-Resistant Pneumococcal Serotype 35B among Children in the United States

Distribution and antimicrobial susceptibility of bacteria from adults with community-acquired pneumonia or complicated skin and soft tissue infections in France: the nationwide French PREMIUM study

Biological and Epidemiological Features of Antibiotic-Resistant Streptococcus pneumoniae in Pre- and Post-Conjugate Vaccine Eras: a United States Perspective

Contact Info

Product

Resources

About